MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients Orally administered MP1032 with very favorable safety and tolerability profile Compound

MetrioPharm’s MP1032 has anti-viral effects on different SARS-CoV-2 Variants of Concern By Dr. Christian Setz, Scientific Managing Director of ImmunoLogik This is the third article

A regulatory strategy for the use of MP1032 in pediatric patients By Dr. Volker Blust, Founder of PHOX Consulting e.U. This is the second article

The Joint Meeting of DGFI & ÖGAI 2022 In September Sara Schumann attended the Joint Meeting of The DGFI Young Immunologists & ÖGAI 2022 where basic immunology met

An automated manufacturing process for MP1032 By Dr. Thies Klüßendorf, Senior Chemistry, Manufacturing, and Controls (CMC) Project Manager, MetrioPharm    This is the first article

Today we will look through the magnifying glass and discover what exactly the iMPact project is about, when it started, who is involved, and where it will go.

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19 The last patient had his/her last visit in MetrioPharm’s trial in COVID-19 on July

MetrioPharm partakes in EU-wide coordination and collaboration meeting for EU-funded projects conducting clinical trials on COVID-19 therapeutics Virtual meeting, April 06, 2022     We are

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19 Zurich, March 02, 2022.   MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory

MetrioPharm Signs European Commission Grant Agreement for €7.9 Million European commission funds COVID project iMPact with 7.9 million euros MetrioPharm will receive a total of